A monoclonal antibody SF5 that specifically recognizes the SPAG protein of Theileria rings and its applications

By developing a monoclonal antibody SF5 that specifically recognizes the SPAG protein of Theileria ringis, and preparing detection kits and test strips, the problem of poor diagnostic and immune intervention effects of bovine ringisia disease in existing technologies has been solved, achieving highly efficient diagnostic and control effects.

CN121426951BActive Publication Date: 2026-11-10LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511674909.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-11-14
Publication Date
2026-11-10
Estimated Expiration
2045-11-14

AI Technical Summary

Technical Problem

Current technologies for treating bovine ring-shaped Theileria disease lack highly effective monoclonal antibodies that specifically recognize the SPAG protein of *Theileria ring-shaped Theileria*, resulting in poor diagnostic and immunomodulatory intervention outcomes.

Method used

A monoclonal antibody, SF5, specifically recognizing the SPAG protein of Theileria ringisii was developed, and corresponding detection kits and test strips were prepared. This antibody was used for the diagnosis and control of bovine ringisii disease.

Benefits of technology

It provides a highly efficient diagnostic tool for bovine ring-shaped Theileria disease, achieving specific recognition of the SPAG protein through the monoclonal antibody SF5, with an M/N value as high as 25.6955, significantly improving the accuracy and efficiency of diagnosis and control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121426951B_ABST
    Figure CN121426951B_ABST
Patent Text Reader

Abstract

This invention relates to the field of biotechnology, specifically to a monoclonal antibody SF5 that specifically recognizes the SPAG protein of *Theileria ringensis* and its applications. The monoclonal antibody SF5 has the following amino acid sequence: heavy chain variable region as shown in SEQ ID No. 1, and light chain variable region as shown in SEQ ID No. 2. The M / N value is as high as 25.6955. The preparation of detection kits or test strips using the monoclonal antibody is of great significance for the diagnosis, prevention, and control of bovine *Theileria ringensis*.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, specifically to a monoclonal antibody SF5 that specifically recognizes the SPAG protein of Theileria rings and its applications. Background Technology

[0002] Theileria rings ( Theileria annulata Theileria is a very important tick-borne protozoan parasite. It can cause bovine annulare disease, also known as Mediterranean coastal fever, an acute, often fatal blood protozoan disease that poses a significant threat to the cattle industry. Its prevention and control hinges on a comprehensive management approach combining vaccination and tick control. Regular medicated baths or sprays with highly effective, low-toxicity tick-killing agents are necessary, along with drug treatment. Bupavaquinone is currently the most effective anti-Theileria drug, capable of killing schizonts and sporozoites, but its effectiveness diminishes after schizont proliferation.

[0003] Theileria rings sporozoite surface antigen (SPAG) is a protein expressed in the sporozoites, schizonts, and erythrocytozoites of Theileria rings, but its expression level is relatively high in the sporozoite stage. SPAG protein is a key molecule initiating infection and a primary target for intercepting infection, diagnosis, and immune intervention. An indirect ELISA method based on recombinant SPAG protein exhibits good specificity and sensitivity and can be used for serological detection and epidemiological surveys of Theileria rings disease.

[0004] The inventor's research group has long been dedicated to the study of *Theileria annularis*, and has conducted in-depth research on the surface proteins of *Theileria annularis* sporozoites. Based on previous research, the inventor conducted further research and obtained a monoclonal antibody SF5 that specifically recognizes the *Theileria annularis* SPAG protein. The antibody titer and reactivity of the obtained antibody were identified, with an M / N value as high as 25.6955. The preparation of detection kits or test strips using the monoclonal antibody is of great significance for the diagnosis, prevention and control of bovine *Theileria annularis* disease. Summary of the Invention

[0005] The primary objective of this invention is to provide a monoclonal antibody SF5 that specifically recognizes the SPAG protein of Theileria rings. The amino acid sequence of the heavy chain variable region of the monoclonal antibody SF5 is shown in SEQ ID No. 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 2.

[0006] A second object of the present invention is to provide a gene fragment encoding the monoclonal antibody SF5.

[0007] A third objective of this invention is to provide an expression cassette, expression vector, and recombinant bacteria containing the aforementioned gene fragment.

[0008] A fourth objective of this invention is to provide the application of the monoclonal antibody SF5, which specifically recognizes the SPAG protein of *Theileria ringensis*, in the specific recognition of the SPAG protein of *Theileria ringensis*.

[0009] A fifth objective of this invention is to provide the use of the monoclonal antibody SF5 in the preparation of reagents for detecting Theileria rings.

[0010] The sixth objective of this invention is to provide the application of the monoclonal antibody SF5 in the preparation of test strips for detecting Theileria rings.

[0011] A seventh objective of this invention is to provide the use of the monoclonal antibody SF5 in the preparation of a kit for detecting Theileria rings.

[0012] The beneficial effects of this invention are as follows: This invention provides a monoclonal antibody SF5 that specifically recognizes the SPAG protein of *Theileria ringensis*. The amino acid sequence of the heavy chain variable region of the monoclonal antibody SF5 is shown in SEQ ID No. 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 2. The M / N value is as high as 25.6955. The preparation of detection kits or test strips using the monoclonal antibody is of great significance for the diagnosis, prevention and control of bovine *Theileria ringensis*. Attached Figure Description

[0013] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the provided drawings without creative effort.

[0014] Figure 1 Monoclonal antibody SF5 recognizes the SPAG protein. Note: M: Protein Marker, 1 is negative serum (SPAG non-immune serum), 2 is SF5 mAb cell supernatant, 3 is positive serum (SPAG hyperimmune serum). Figure 2 Indirect immunofluorescence detection of the reaction between monoclonal antibody SF5 and native proteins of Theileria rings Note: NC is the negative control (primary antibody is negative serum), SF5 is the experimental group (primary antibody is SF5 mAb cell supernatant), and PC is the positive control (primary antibody is positive serum). Detailed Implementation

[0015] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0016] Unless otherwise specified, the experimental methods used in the embodiments are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following embodiments are commercially available.

[0017] Example 1: Preparation and Validation of Monoclonal Antibodies 1. Biotinylation of SPAG protein

[0018] The SPAG gene from *Theileria rings*, recombined with the prokaryotic expression vector (pET-30a), expressed a protein approximately 42 kDa. Frozen SPAG plasmids were transformed into DH5α competent cells. After thawing, the cells were transferred to 200 mL of kanamycin-resistant LB medium and cultured at 37°C and 200 rpm for 8 h. Cells were collected by centrifugation, the supernatant was discarded, and PBS buffer was added and mixed. The cells were then sonicated and centrifuged again to collect the supernatant, which was then incubated overnight at 4°C with Ni-NTA packing material. The supernatant was eluted with pre-prepared imidazole at different concentrations, and the purified product was analyzed by protein electrophoresis. The SPAG protein was then transferred to PBS buffer using a dialysis bag with a molecular weight cutoff of 12-14 kDa, and concentrated using PEG 6000. The protein concentration was determined to be 1.6 mg / mL using the BCA method.

[0019] Add 1 μL of 10 mM biotin to 1 mL of 1.6 mg / mL SPAG protein, incubate on ice for 2 h, then transfer the labeled SPAG protein to PBS buffer using an ultrafiltration tube. Add an equal volume of 100% glycerol and store at -80°C. Western blot was used to determine successful labeling of the biotin-labeled SPAG protein, using HRP-labeled streptavidin as the secondary antibody.

[0020] 2. Isolation of bovine peripheral blood mononuclear cells

[0021] Bovine jugular vein blood was collected after four immunizations. The plasma and leukocyte layer between the red blood cells were separated by centrifugation at 2000 rpm / min for 25 min at 25°C and transferred to a 50 mL sterile centrifuge tube. The cell suspension was diluted with PBS buffer and slowly added to a 15 mL sterile centrifuge tube containing 4 mL Ficoll, until the final volume was 10 mL. The cells were then centrifuged at 400 rpm / min at 2°C for 40 min, and the supernatant was discarded. 1 mL of sterile distilled water was added to lyse the remaining red blood cells. After mixing, PBS buffer was immediately added, and the cells were centrifuged at 1000 rpm / min at 25°C for 10 min. The supernatant was discarded, and this process was repeated until the red blood cells were completely lysed. Peripheral blood mononuclear cells (PBMCs) were diluted to 10⁻⁶ with PBS buffer. 7 Place each sample / mL into a 1.5 mL centrifuge tube.

[0022] 3. SPAG protein-specific single B cell screening

[0023] PBMCs were divided into 6 tubes: 1 tube was a blank control, and 3 tubes were single-stained tubes, containing CD21 and CD21 respectively. + SPAG + IgM + One tube was the FMO control, and the other was the sorting sample tube. The cell concentration was adjusted to 102. 7 One cell was evenly distributed into 200 μL of cell sorting medium (MACS), and 0.5 μg of biotin-labeled SPAG protein was added. The cells were incubated on ice in the dark for 30 min. After centrifugation at 1000 rpm / min for 5 min at 4°C, the cells were washed once with MACS. Then, 5 μL of mouse anti-bovine CD21-RPE antibody, 1 μL of FITC-labeled goat anti-bovine IgM antibody, and 20 μL of APC-labeled antibiotin antibody were added. The mixture was incubated on ice in the dark for 30 min. The cells were washed once more with MACS, resuspended in 400 μL of MACS, and incubated on ice in the dark. Single-stain tubes and an FMO control were set up. Sorting was performed using a BD FACS Aria II flow cytometer, with compensation adjusted, in single-cell sorting mode, and an 85 μm nozzle selected for IgM sorting. - / CD21 + / SPAG + A single B lymphocyte.

[0024] 4. Identification of monoclonal antibodies

[0025] Western blot analysis of mAb expression The harvested cell supernatant was added to protein loading buffer (containing DTT), boiled at 100℃ for 10 min, and 10 μL was added to a prepared 10% protein gel. After electrophoresis at 80 V for 30 min in 1×SDS-PAGE, the voltage was adjusted to 125 V for 1 h to complete the SDS-PAGE denaturing electrophoresis. After wet transfer at 200 mA for 120 min, the protein sample was transferred to a PVDF membrane and blocked with 5% skim milk at room temperature for 1 h. After washing 3 times in 1×TBST, the sample was incubated at room temperature for 1 h with mouse anti-Myc tag monoclonal antibody as the primary antibody (diluted at 1:4000), followed by washing 3 times in 1×TBST. After incubation at room temperature for 40 min with HRP-labeled goat anti-mouse IgG as the secondary antibody (diluted at 1:5000), the sample was washed 3 times in 1×TBST, and the results were observed by ECL reagent.

[0026] (2) Qualitative detection of mAb titer using indirect ELISA Purified SPAG protein (1.6 mg / mL) was used as the coating antigen, the supernatant of each SPAG mAb cell was used as the primary antibody, HRP-labeled rabbit anti-bovine IgG (1:40,000) was used as the secondary antibody, and SPAG hyperimmune serum was used as the positive control. An M / N value (sample well D value / negative well D value) greater than or equal to 2.1 was considered positive; an M / N value between 2.1 and 1.5 was considered suspicious; and an M / N value less than 1.5 was considered negative.

[0027] The recombinant plasmids pcDNA3.4-VH and pcDNA3.4-VL, which showed positive results from indirect ELISA, were co-transfected at a density of 2 × 10⁻⁶ mAbs at a ratio of 1:1 (10 μg each) to a concentration of 2 × 10⁻⁶ mAbs per mL. 6 In 20 mL HEK-293T cells, the cell culture medium was changed 4 hours after transfection. The cell supernatant was collected 48 h after transfection, and each mAb was concentrated using a dialysis bag with a molecular weight cutoff of 12-14 kD to a final volume of 1 mL. The cells were then stored at -20 °C.

[0028] (3) Reactivity identification of SPAG protein After completing SDS-PAGE denaturing electrophoresis of SPAG protein, the protein was wet-transferred to a PVDF membrane. The original supernatant of each SPAG mAb cell was used as the primary antibody, HRP-labeled rabbit anti-bovine IgG (1:5000) was used as the secondary antibody, and mouse anti-His-tagged monoclonal antibody was used as the control. The results were observed by ECL reagent.

[0029] Indirect immunofluorescence assay for antibody reactivity Lymphocytes transformed with Theileria rings were revived. After the cell density reached 70%, the supernatant was discarded. The cells were fixed with 4% paraformaldehyde for 30 min, washed three times with 1×PBS, permeabilized with 0.5% Triton X-100 for 5 min, washed three times, blocked with 3% BSA at 37℃ for 30 min, and concentrated cell supernatant was added as the primary antibody. Hyperimmune serum was used as the positive control, and cell supernatant from cells not transfected with the two plasmids was used as the blank control. The cells were incubated at 37℃ for 1 h, washed five times with 1×PBS, and DAPI nuclear staining reagent and mouse anti-bovine IgG / S Alexa Fluor 488 were added as secondary antibodies at a ratio of 1:1000. The cells were incubated at 37℃ for 1 h, washed three times with 1×PBS buffer, and the results were observed under a fluorescence inverted microscope.

[0030] 5. Results

[0031] (1) PCR amplification results of MAb light and heavy chain variable region sequences 2% agarose gel electrophoresis results showed that the light and heavy chain variable regions of mAbs were naturally paired. The amino acid sequence of the light chain variable region was: QAVLTQPSSVSGSLGQRVSITCSGGSSNVGRGNYVNWFQHIPGSAPRTLIYGATTQASGVPDRFSGSRSGDTATLTISSLQAEDEAVYFCAAYDSAGVSIFGSGTTLTVL (SEQ ID No. 2); the amino acid sequence of the heavy chain variable region was: QVQLRESGPSLVKPSQTLSLTCTVSGFSLSNYAVGWVRQAPGKALEWVGSRRPDGATCYNPSLKSRLSITRDTSKSQVSLSVSSVTPEDTATYYCASFVCGFGVGCYGYDFLESYVDAWGQGLLVTVSS (SEQ ID No. 1).

[0032] (2) Indirect ELISA detection of mAb titer The results of indirect ELISA are shown in Table 1. The M / N value of the monoclonal antibody SF5 against SPAG protein was as high as 25.6955.

[0033] Table 1. Identification of positive and negative results for monoclonal antibody SF5 against SPAG protein.

[0034] (3) Identification of the reactivity of SPAG protein Figure 1Western blot results showed that both SF5 mAb (lane 2) and SPAG hyperimmune serum (lane 3) reacted with the target protein SPAG, producing a specific band of 42 kDa. Unimmunized serum did not react with SPAG protein, indicating that SF5 mAb can specifically recognize the Theileria rings antigen SPAG (e.g., ...). Figure 1 ).

[0035] (4) Identification of monoclonal antibody SF5 by indirect immunofluorescence assay IFAT results showed that SF5 mAb (lane 2) and SPAG hyperimmune serum (lane 3) both exhibited specific green fluorescence after incubation with lymphocytes transformed by *Theileria rings*, while no specific green fluorescence was observed after incubation with unimmunized serum. This indicates that SF5 mAb can recognize the natural SPAG protein secreted by *Theileria rings* (such as...). Figure 2 (As shown).

[0036] In summary, this invention provides a monoclonal antibody SF5 that specifically recognizes the SPAG protein of *Theileria ringensis*. The amino acid sequence of the heavy chain variable region of the monoclonal antibody SF5 is shown in SEQ ID No. 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 2. The M / N value is as high as 25.6955. The preparation of detection kits or test strips using the monoclonal antibody is of great significance for the diagnosis, prevention, and control of bovine *Theileria ringensis*.

Claims

1. A monoclonal antibody SF5 that specifically recognizes the SPAG protein of Theileria rings, characterized in that, The amino acid sequence of the heavy chain variable region of the monoclonal antibody SF5 is shown in SEQ ID No. 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID No.

2.

2. The gene encoding the monoclonal antibody SF5 as described in claim 1.

3. An expression cassette, expression vector, or recombinant bacteria containing the gene described in claim 2.

4. The use of the monoclonal antibody SF5 as described in claim 1 in the preparation of reagents for detecting Theileria rings.

5. The use of the monoclonal antibody SF5 as described in claim 1 in the preparation of a test strip for detecting Theileria rings.

6. The use of the monoclonal antibody SF5 as described in claim 1 in the preparation of a kit for detecting Theileria rings.

Citation Information

Patent Citations

  • Preparation and application of monoclonal antibody for resisting theileria annulata SPAG protein

    CN118440193A

  • Monoclonal antibody to surface protein p32 of thei leria sergenti

    JP1999089571A